Article
Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.
Cancer research - 15 Dec 2014
Ferrari de Andrade Lucas, Ngiow Shin F, Stannard Kimberley, Rusakiewicz Sylvie, Kalimutho Murugan, Khanna Kum Kum, Tey Siok-Keen, Takeda Kazuyoshi, Zitvogel Laurence, Martinet Ludovic, Smyth Mark J
Abstract excerpt
BRAF(V600E) is a major oncogenic mutation found in approximately 50% of human melanoma that confers constitutive activation of the MAPK pathway and increased melanoma growth. Inhibition of BRAF(V600E) by oncogene targeting therapy increases overall survival of patients with melanoma, but is unable to produce many durable responses. Adaptive drug resistance remains the main limitation to BRAF(V600E) inhibitor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.